Skip to Content

Tag Archives: drugs

Bitter Pill for Pfizer

Even the best and the brightest can stumble. Need proof? Just chew on the latest news from Pfizer (NYSE: PFE). Over the weekend, PFE announced it was halting development of the most promising drug in its pipeline, torcetrapib. However, I am hopeful but realistic that PFE can regain the offensive and grow its business again within a reasonable time frame.

Pfizer Under the Microscope

I’m not, ordinarily, a fan of big companies’ annual reports. There’s way too much puffery, and far too little substance. However, I’m intrigued by an exception this year. Pfizer (NYSE: PFE), under the gun from regulators, investors and various other constituencies, has put out a remarkable little booklet called Ten Questions. In the report, the company tries to address, head-on, some of the sharpest criticisms leveled against itself and the pharmaceutical industry.

MAJOR BOTTOM FOR DRUG STOCKS?

For a number of weeks, P/E ratios (and other valuation yardsticks) for the big-name pharmaceutical stocks have shriveled to multiyear lows. Now we seem to be approaching a downside climax.

WHAT'S THE TRUTH ABOUT CELEBREX?

Wall Street was wringing its hands again today over Pfizer (NYSE: PFE). A report in a Canadian newspaper, the National Post, said PFE’s pain-killing arthritis drug, Celebrex, was linked to 14 deaths. The article cited documents that Canadian health authorities use to track adverse reactions to drugs.

WHAT’S THE TRUTH ABOUT CELEBREX?

Wall Street was wringing its hands again today over Pfizer (NYSE: PFE). A report in a Canadian newspaper, the National Post, said PFE’s pain-killing arthritis drug, Celebrex, was linked to 14 deaths. The article cited documents that Canadian health authorities use to track adverse reactions to drugs.